Medical technology company MGC Diagnostics has secured the US Food and Drug Administration (FDA) 510(k) clearance for its Resmon PRO FULL, Forced Oscillation Technique (FOT) device.

The device enables US healthcare professionals to non-invasively monitor a patient’s lung mechanics and normal breathing pattern, eliminating the need of forced efforts with traditional measurements.

The Resmon PRO FULL is suited for use for elderly patients as well as children aged four and above.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The device is suitable for critically ill patients as it requires less patient movement during the process.”

MGC Diagnostics CEO Todd Austin said: “The Resmon PRO FULL is designed to provide medical professionals the ability to measure mechanical properties of the respiratory system during normal tidal breathing, providing a simple, effort-independent assessment for both clinicians and patients.”

Developed by Restech Respiratory Technology, the FOT features low dead space circuit which is aligned to anxiety tension state (ATS) and erythrocyte sedimentation rate (ERS) standards.

It supplements spirometry with information on mechanical properties of the respiratory system that otherwise may not be accessible via the conventional pulmonary function tests.

The device is suitable for critically ill patients as it requires less patient movement during the process.

The existing spirometry maneuver can hinder the effectiveness of a bronchodilator while the tidal breathing manuever of FOT has the ability to pronounce the effectiveness of a bronchodilator.